Arrakis Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Arrakis Therapeutics's estimated annual revenue is currently $20.1M per year.
- Arrakis Therapeutics received $38.0M in venture funding in February 2017.
- Arrakis Therapeutics's estimated revenue per employee is $201,000
- Arrakis Therapeutics's total funding is $113M.
- Arrakis Therapeutics has 100 Employees.
- Arrakis Therapeutics grew their employee count by 23% last year.
Arrakis Therapeutics Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Arrakis Therapeutics?
Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. The company's TRYST and PEARL-seq platforms identify new RNA targets and drug candidates to treat diseases unaddressed by today's medicines. Arrakis is developing a proprietary pipeline of RNA-targeted small molecules focused on neurologic diseases, cancer, and rare genetic diseases. Arrakis was founded in 2015 by Russell Petter, Ph.D., Alan Walts, Ph.D., Henri Termeer and Raj Parekh, Ph.D. with a vision to create a proprietary, transformational discovery platform that identifies small-molecule drugs that act directly on disease-causing RNA. The company was established with seed funding provided by Advent Life Sciences and Henri Termeer. The company brings together scientific leaders in RNA structure, chemistry and biology, along with a highly experienced management team and the backing of leading life sciences investors. The company is located in Waltham, Mass.keywords:N/A
Number of Employees
Employee Growth %
Arrakis Therapeutics News
... occupiers including Arrakis Therapeutics, Synlogic Therapeutics, Celgene, MISPRO Biotech, and Cerevel Therapeutics, among others.
... who soon thereafter founded Arrakis Therapeutics, where she is chief innovation officer. What made the problem interesting to her was,...
Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA.
“We are excited to partner with Roche’s strong research and development teams,” Arrakis CEO Michael Gilman said in a statement. “Together, we share a common vision of accessing new drug targets at the RNA level and thereby discovering novel medicines to treat diseases with high unmet medical nee ...
Michael Gilman, a partner in Atlas Venture, will become full-time CEO of the company, which is named for the fictional planet of Arrakis in Frank Herbert’s “Dune” science fiction series, the planet being the source of the fictional substance spice melange. The company completed a $38 million Ser ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Arrakis Therapeutics Funding